{{Rsnum
|rsid=1866813
|Chromosome=3
|position=137083096
|Orientation=minus
|GMAF=0.1777
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 0.9 | 22.3 | 76.8
| HCB | 5.3 | 39.8 | 54.9
| JPT | 9.9 | 45.0 | 45.0
| YRI | 0.0 | 14.3 | 85.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 5.3 | 39.8 | 54.9
| CHD | 3.7 | 32.4 | 63.9
| GIH | 5.0 | 34.7 | 60.4
| LWK | 0.0 | 14.5 | 85.5
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 16.0 | 84.0
| TSI | 2.0 | 21.6 | 76.5
| HapMapRevision=28
}}{{omim
|desc=MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 1; MVCD1
|id=603933
|rsnum=1866813
}}

{{PharmGKB
|RSID=rs1866813
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19084216
|Annotation=In a multi-stage case-control study of Type I Diabetes Mellitus patients from Finland,Iceland and the British Isles, the C allele of rs1866813 was associated with increased risk of Diabetic Nephropathy (overall p = 7.07 x 10( -6); combined OR of the allele = 1.33).
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 1; Diabetic Nephropathies
|Curation Level=Curated
|PharmGKB Accession ID=PA164857067
}}

{{PMID Auto
|PMID=20667095
|Title=Effects of MCF2L2, ADIPOQ and SOX2 genetic polymorphisms on the development of nephropathy in type 1 Diabetes Mellitus.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1866813
|overall_frequency_n=17
|overall_frequency_d=126
|overall_frequency=0.134921
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=15
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23441190
|Title=A Remote Cis-Acting Variant at 3q Links Glomerular NCK1 to Diabetic Nephropathy
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}